AI Engines For more Details: Perplexity Kagi Labs You
Antihypertensive Effect: Methyldopa is effective in lowering blood pressure by acting on the central nervous system. It works by stimulating alpha-2 adrenergic receptors in the brain, which reduces sympathetic nervous system activity and leads to vasodilation (relaxation of blood vessels). This results in a decrease in peripheral resistance and ultimately lowers blood pressure.
Long-Term Management of Hypertension: Methyldopa is commonly used for the long-term management of hypertension. It helps to prevent complications associated with high blood pressure, such as heart disease, stroke, and kidney damage.
Slow Onset of Action: Methyldopa typically has a slow onset of action, with the full antihypertensive effect usually taking several hours to develop. Therefore, it may not be suitable for the rapid reduction of blood pressure in emergency situations.
Reduction of Cardiovascular Risk: By lowering blood pressure, methyldopa helps to reduce the risk of cardiovascular events such as heart attacks and strokes.
Side Effects: Like any medication, methyldopa can cause side effects. Common side effects may include:
Rare Side Effects: In rare cases, methyldopa may cause more serious side effects, such as:
Contraindications: Methyldopa is contraindicated in individuals with a history of hypersensitivity to methyldopa or any other component of the formulation. It should also be avoided in patients with active liver disease or a history of depression.
Dosage and Administration: The dosage of methyldopa is individualized based on the patient's blood pressure response and tolerance to the medication. It is usually taken orally in the form of tablets or capsules, with dosing typically divided into two or three doses per day.
Pregnancy and Breastfeeding: Methyldopa is often considered one of the preferred antihypertensive medications for use during pregnancy. However, it should be used with caution, and the benefits and risks should be carefully weighed by healthcare providers. Methyldopa may pass into breast milk, so breastfeeding mothers should consult their healthcare provider before using this medication.
Monitoring: Patients taking methyldopa should be monitored regularly by their healthcare provider to assess blood pressure control and monitor for any signs of adverse effects or complications.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 0.6 | 0.3 | 1 |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.3 | 1 |
| Allergies | 1 | 0.3 | 2.33 |
| Allergy to milk products | 0.3 | 0.3 | |
| Alzheimer's disease | 1 | 0.6 | 0.67 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | |
| Ankylosing spondylitis | 0.3 | 0.3 | 0 |
| Anorexia Nervosa | 0.3 | 0.3 | 0 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 0.9 | 0.3 | 2 |
| Atherosclerosis | 0.3 | 0.3 | |
| Atrial fibrillation | 0.6 | 0.6 | |
| Autism | 0.9 | 0.9 | 0 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 0.3 | -0.3 | |
| Brain Trauma | 0.3 | 0.3 | |
| Breast Cancer | 1 | 1 | |
| Cancer (General) | 0.3 | 0.6 | -1 |
| Carcinoma | 1.2 | 1.2 | |
| Celiac Disease | 0.3 | 0.3 | |
| Cerebral Palsy | 0.3 | 0.3 | |
| Chronic Fatigue Syndrome | 0.6 | 0.9 | -0.5 |
| Chronic Kidney Disease | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 0.9 | 0.33 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | 0 |
| Cognitive Function | 0.3 | 0.3 | 0 |
| Colorectal Cancer | 1.6 | 1.6 | |
| Coronary artery disease | 0.3 | 0.3 | 0 |
| COVID-19 | 0.6 | 0.9 | -0.5 |
| Crohn's Disease | 1.5 | 0.6 | 1.5 |
| deep vein thrombosis | 1 | 0.3 | 2.33 |
| Denture Wearers Oral Shifts | 1.3 | 1.3 | |
| Depression | 1.5 | 1.5 | 0 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.6 | 0 |
| Endometriosis | 0.6 | 0.3 | 1 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 0.6 | 0.6 | |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.3 | -0.3 | |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.3 | 1 |
| gallstone disease (gsd) | 0.3 | -0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.3 | 2.33 |
| Generalized anxiety disorder | 0.9 | 0.6 | 0.5 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 0.6 | -0.6 | |
| Gulf War Syndrome | 0.6 | 0.6 | |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 0.3 | 0.3 | |
| Heart Failure | 1.2 | 1.2 | |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| hyperglycemia | 0.4 | 0.4 | |
| hypertension (High Blood Pressure | 0.3 | 0.6 | -1 |
| Hypothyroidism | 0.3 | -0.3 | |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | |
| Inflammatory Bowel Disease | 1.6 | 0.9 | 0.78 |
| Insomnia | 0.9 | 0.3 | 2 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 1 | 0.6 | 0.67 |
| ischemic stroke | 0.3 | 0.3 | |
| Liver Cirrhosis | 1.2 | 0.9 | 0.33 |
| Long COVID | 0.9 | 0.6 | 0.5 |
| Low bone mineral density | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 1 | 0.3 | 2.33 |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.3 | |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 0.9 | 0.9 | 0 |
| Mood Disorders | 1.5 | 1.5 | 0 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 1.6 | 0.6 | 1.67 |
| myasthenia gravis | 0.3 | 0.3 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.3 | 1 |
| Obesity | 0.9 | 2.5 | -1.78 |
| obsessive-compulsive disorder | 0.3 | 0.6 | -1 |
| Osteoarthritis | 0.3 | 0.3 | 0 |
| Osteoporosis | 0.3 | -0.3 | |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 0.9 | 0.9 | 0 |
| Polycystic ovary syndrome | 0.9 | 0.3 | 2 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 0.6 | 0.3 | 1 |
| Psoriasis | 0.3 | 0.3 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.2 | 0.6 | 1 |
| Schizophrenia | 0.9 | 0.3 | 2 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 0.3 | 0.3 | |
| Sleep Apnea | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.3 | 0 |
| Systemic Lupus Erythematosus | 0.9 | 0.9 | |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.6 | 0.3 | 1 |
| Type 2 Diabetes | 1.5 | 0.9 | 0.67 |
| Ulcerative colitis | 1 | 0.3 | 2.33 |
| Unhealthy Ageing | 1.5 | 0.3 | 4 |
| Vitiligo | 0.3 | 0.3 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
